Oxford BioMedica PLC (OXB.L) Quote| Reuters.com
Edition:
United States

Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

4.43GBp
11:38am EDT
Change (% chg)

-0.27p (-5.74%)
Prev Close
4.70p
Open
4.35p
Day's High
4.52p
Day's Low
4.35p
Volume
1,648,198
Avg. Vol
2,377,754
52-wk High
10.96p
52-wk Low
3.65p

OXB.L

Chart for OXB.L

About

Oxford BioMedica plc is a United Kingdom-based gene and cell therapy research and development business. The Company is lentiviral vector and cell therapy research, development and manufacture. It provides a platform of technologies and capabilities with which it designs, develops and manufactures gene and cell-based medicines.... (more)

Overall

Beta: 0.60
Market Cap(Mil.): £127.05
Shares Outstanding(Mil.): 2,703.15
Dividend: --
Yield (%): --

Financials

  OXB.L Industry Sector
P/E (TTM): -- 42.29 36.15
EPS (TTM): -0.01 -- --
ROI: -41.16 -6.23 14.31
ROE: -76.73 -5.61 15.51

BRIEF-Oxford BioMedica grants to MolMed non-exclusive licence under its LentiVector platform technology

* Signs with Oxford BioMedica new non-exclusive licence agreement concerning lentiviral vector technology

Jun 07 2016

BRIEF-Oxford Biomedica says Chief Development Officer Blake to leave in Aug

* Announces that Dr Paul Blake will leave group when his current contract expires at end of August 2016.

May 12 2016

BRIEF-Oxford Biomedica presents lentivector gene therapy data

* Presents ground-breaking evidence of long-term duration of therapeutic expression in patients from lentivector gene delivery platform Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

May 06 2016

BRIEF-Oxford Biomedica FY gross income up 28 pct

* Oxford biomedica: preliminary results for year ended 31 December 2015

Apr 28 2016

BRIEF-Oxford Biomedica expands deal with Immune Design

* Oxford Biomedica announces expanded collaboration and licence with Immune Design

Mar 07 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Wright Reports
$75.00
Provider : Sadif Analytics Prime
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.